Human immunodeficiency virus and the central nervous system

Brazilian Journal of Infectious Diseases

Volumn 10, Issue 1, 2006, Pages 41-50

  de Almeida, Sergio Monteiro ^a,b,c   Letendre, Scott ^b   Ellis, Ron ^b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

AIDS; Central nervous system; Cerebrospinal fluid; Chemokines; HIV; HIV dementia; Viral load

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIOXIDANT; CHEMOKINE; CPI 1189; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SELEGILINE; STAVUDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; AIDS RELATED COMPLEX; ASTROCYTE; BLOOD BRAIN BARRIER; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLINICAL TRIAL; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; EPIDEMIC; ETHNIC GROUP; EXTRACELLULAR SPACE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INCIDENCE; INTRAVENOUS DRUG ABUSE; MONOCYTE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; VIRUS LOAD; VIRUS MENINGITIS; VIRUS VIRULENCE;

AIDS-RELATED COMPLEX; ANTI-RETROVIRAL AGENTS; CENTRAL NERVOUS SYSTEM VIRAL DISEASES; CHEMOKINES; HIV INFECTIONS; HIV-1; HUMANS; MENINGITIS, VIRAL; MIDDLE AGED; RISK FACTORS; VIRAL LOAD;

EID: 33745068691     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702006000100009     Document Type: Review

References (88)

1. Szwarcwald C.L., Bastos F.I., Esteves M.A.P., Andrade C.L.T.A. Dissemina̧tiao da epidemia de aids no Brasil, no período de 1987-1996: uma análise espacial. Cadernos de Saúde Publica 2000;16(suppl 1):7-19.
2. Ribeiro C.E.L. Impacto da aids na mortalidade de mulheres no município de Curitiba [M.Sc. thesis]. Curitiba (PR): UFPR, 2001.
3. Soto Ramirez L.E. Physiopathology and treatment of acquired immunodeficiency syndrome. Rev Invest Clin 2000;52:60-71.
4. Power C., McArthur J.C., Johson R.T., et al. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type1 envelope sequences. Journal of Virology 1994;68:4643-9.
5. Alaeus A. Significance of HIV-1 genetic subtypes. Scandinavian Journal of Infectious Disease 2000;32:455-63.
6. Cahn P., Belloso W.H., Murillo J., Prada-Trujillo G. AIDS in Latin America. Infectious Disease Clinics of North America 2000;14:185-209.
7. Antunes C.C., Cecchni F.M., Bolli F.B., et al. Cerebral trypanosomiasis and AIDS, Arquivos de Neuropsiquiatria 2002;60:730-3.
8. Cohen J.E., Tsai E.C., Ginsberg H.J., Godes J. Pseudotumoral chagasic meningoencephalitis as the first manifestation of acquired immunodeficiency syndrome. Surgical Neurology 1998;49:324-7.
9. Di Lorenzo G.A., Pagano M.A., Taraturo A.L., et al. Chagasic granulomatous encephalitis in immunosuppressed patients. Computed tomography and magnetic resonance imaging findings. Journal of Neuroimaging 1996;6:94-7.
10. Gallo P., Fabiao Neto O.M., et al. Acute central nervous system infection by Trypanosoma cruzi and AIDS. Arq Neuropsiquiatr 1992;50:375-7.
11. Gluckstein D., Ciferri F., Ruskin J. Chaga's disease: another cause of cerebral mass in the acquired immunodeficiency syndrome. American Journal of Medicine 1992;92:429-32.
12. Lazo J., Meneses A.C., Rocha A., et al. Chagasic meningoencephalitis in the immunodeficient. Arquivos de Neuropsiquiatria 1998;56:93-7.
13. Lazo J., Meneses A.C., Rocha A., et al. Toxoplasmic and chagasic meningoencephalitis in patients with human immunodeficiency virus infection: anatomopathologic and tomographic differential diagnosis. Revista da Sociedade Brasileira de Medicina Tropical 1998;31:163-71.
14. Lages-Silva E., Ramirez L.E., Silva Vergara M.L., Chiari E. Chagasic meningoencephalitis in a patient with acquired immunodeficiency syndrome: diagnosis, follow up, and genetic characterization of Trypanosoma cruzi. Clinical Infectious Disease 2002;34:118-23.
15. Pagano M.A., Segura M.J., Di Lorenzo G.A., et al. Cerebral tumor-like american trypanosomiasis in acquired immunodeficiency syndrome. Annals of Neurology 1999; 45:403-6.
16. Pimentel P.C., Handfas B.W. Carmignani M. Trypanosoma cruzi meningoencephalitis in AIDS mimicking cerebral metastases: case report. Arquivos de Neuropsiquiatria 1996;54:102-6.
17. Rosemberg S., Chaves C.J., Higuchi M.L., et al. Fatal meningoencephalitis caused by reactivation of Trypanosoma cruzi infection in a patient with AIDS. Neurology 1992;42:640-2.
18. Silva N., O'Bryan L., Medeiros E., et al. Trypanosoma cruzi meningoencephalitis in HIV-infected patients. Journal of AIDS and Hum Retrovirology 1999;20:342-9.
19. Bernard G., Duarte A.J. Paracoccidiodomycosis: a model for evaluation of the effects of human immunodeficiency virus infections on the natural history of endemic tropical diseases. Clinical Infectious Diseases 2000;31:1032-9.
20. Finamor L.P., Muccioli C., Martins M.C., et al. Ocular and central nervous system paracoccidioidomycosis in a pregnant woman with AIDS. American Journal of Ophtalmology 2002; 134: 456-9.
21. Navia B.A., Jordan B.D., Price R.W. The AIDS dementia complex: I clinical features. Annals of Neurology 1986;19:517-24.
22. Petito C.K., Cho E.S., Lemann W., et al. Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. Journal of Neuropathology and Experimental Neurology 1986:45;635-46.
23. Vitkovic L., Tardieu M. Neuropathogenesis of HIV-1 infection. Outstanding questions. C R Acad Sci III 1998;321:1015-21.
24. Berger J.R., Levy R.M. Editors. AIDS & the nervous system. Philadelphia: Lippincott - Raven, 2 ed; 1997.
25. Brew B.J., Pemberton L., Cunninghan P., Law M.G. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. Journal of Infectious Diseases 1997; 175:963-6.
26. Gendelman H.E., Lipton S.A., Epstein L., Swindells S. Editors (1998). The neurology of AIDS. New York: Chapman & Hall, 1998.
27. Ho D.D., Byington R.E., Schooley R.T., et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. New England Journal of Medicine 1985;313:1493-7.
28. Resnick L., DiMarzo-Veronese F., Tourtellotte W.W., et al. Intrablood-brain-barrier synthesis of HTLV-III specific IgG in patients with neurologic symptons associated with AIDS or AIDS-related complex. New England Journal of Medicine 1985;313:1498-504.
29. Gonda M.A., Wong S.F., Gallo R.C., et al. Sequence homology and morphologic similarity of HTLV-III and Visna virus, a pathogenic Lentivirus. Science 1985;227:173-7.
30. Marshall D.W., Brey R.L., Cahill W.T., et al. Spectrum of cerebrospinal fluid in various stages of human immunodeficiency virus infection. Archives of Neurology 1988;45:954-8.
31. Resnick L., Berger J.R., Shapshak P., Tourtellotte W.W. Early penetration of the blood brain barrier by HIV. Neurology 1988;38:9-14.
32. Evans K.E., Donley D.K., Whitaker J.N. Neurological manifestations of infection with the Human Immunodeficiency viruses. In: Scheld WM, Whitley RJ, Durack DT. Infections of the Cetral Nervous System. New York; Raven Press; 1991, p 201-32.
33. Carne C.A., Tedder R.S., Smith A., et al. Acute encephalopathy coincident with seroconversion for anti- HTLV-III. Lancet 1985;2:1206-8.
34. Fishman R.A. Cerebrospinal fluid in diseases of the nervous system. 2ed. Philadelphia. W.B. Saunders, 1992.
35. McArthur J.C. Neurologic manifestations of AIDS. Medicine 1987;66:407-37.
36. Price R.W. The two faces of HIV infection of cerebrospinal fluid. Trends in Microbiology 2000;8:387-90.
37. Brew B.J., Wesselingh S.L., Gonzales M., et al. How HIV leads to neurological disease. MJA 1996;164:233-4.
38. Cross A.K., Woodroofe M.N. Chemokine modulation of matrix metalloproteinases and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. Glia 1999;28:183-9.
39. Paul R., Lorenzl S., Koedel U., et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Annals of Neurology 1998;44:592-600.
40. Stingele K., Haas J., Zimmermann T., et al. Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy. Neurology 2001;56:355-61.
41. Wong J.K., Günthard H.F., Ellis R.J., et al. The development and trafficking of multi-drug resistant HIV in plasma and CSF during the failure of combination antiviral therapy. Antiviral Therapy 1999;4 (1):76-7.
42. Bajetto A., Bonavia R., Barbero S., et al. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 2001;22:147-84.
43. Bajetto A., Bonavia R., Barbero S., Schettini G, Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. Journal of Neurochemistry 2002;82:1311-29.
44. Biber K., Zuurman M.W., Dijkstra I.M., Boddeke H.W. Chemokines in the brain: neuroimmunology and beyond. Current Opinion in Pharmacology 2002;2:63-8.
45. Gabuzda D., He J., Ohagen A., Vallat A.V. Chemokine receptors in HIV-1 infection of the central nervous system. Seminars in Immunology 1998;10:203-13.
46. Hicks A., Potula R., Sui Y.J., et al. Neuropathogenesis of lentiviral infection in macaques: roles of CXCR4 and CCR5 viruses and interleukin-4 in enhancing monocyte chemoattractant protein-1 production in macrophages. American Journal of Pathology 2002;161:813-22.
47. Corasaniti M.T., Bagetta G, Rotiroti D., Nisticò G. The HIV envelope protein gp 120 in the nervous system: interactions with nitric oxide, interleukin-1BETA and nerve growth factor signaling, with pathological implications in vivo and in vitro. Biochemistry Phamacol 1998;56:153-6.
48. Dawson T.M., Dawson V.L. Gp 120 neurotoxicity in primary cortical cultures. Advances in Neuroimmunology 1994;4; 167-73.
49. Tyler K.L., McArthur J.C. Through a glass, darkly: cerebrospinal fluid viral load measurements and the pathogenesis of human immunodeficiency virus infection of the central nervous system. Archives of Neurology 2002;59:909-12.
50. Karpus W.J. Chemokines and central nervous system disorders. Journal of Neurovirology 2001;7:493-500.
51. Kaul M., Lipton S.A. Chemokines and activated macrophages in HIV gp12O-induced neuronal apoptosis. Proceedings of the National Academy of Sciences of the United States of America 1999;96:8212-6.
52. Letendre S.L., Lanier E.R., McCutchan J.A. Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. Journal of Infectious Diseases 1999;180:310-9.
53. Glass J.D., Wesslingh S.L. Viral load in HIV-associated dementia. Annals of Neurology 1998;44:150-1.
54. Nath A. Pathobiology of human immunodeficiency virus dementia. Seminnars of Neurology 1999;19:113-27.
55. Patel C.A., Mukhtar M., Pomerantz R.J. Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. Journal of Virology 2000;74:9717-26.
56. Power C., Kong P.A., Crawford T.O., et al. Cerebral white matter changes in Acquired immunodeficiency syndrome dementia: alterations of the blood brain barrier. Annals of Neurology 1993;34:339-50.
57. Petito C.K. Neuropathology of human immunodeficiency virus: questions and answers. Human Pathology 1996:27;623-4.
58. Torres-Munoz J.E., Redondo M. Czeisler C., et al. Upregulation of glial clustering in brains of patients with AIDS. Brain Research 2001;888:297-301.
59. Dore G.J., Correll P.K., Li Y., Kaldor J.M., et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999; 13:1249-53.
60. Abbott N.J. Glia and the blood-brain barrier. Nature 1987;325:195.
61. Dana Consortium on therapy for HIV dementia and related cognitive disorders. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1 associated cognitive/motor disorder. Neurology 1996;47:1247-53.
62. McClernon D.R., Lanier R., Gartner S., et al. HIV in the brain: RNA levels and patterns of zidovudine resistance. Neurology 2001;57:1396-401.
63. Tambussi G, Gori A.,Capiluppi B., et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clinical Infectious Diseases 2000;30:962-5.
64. Ellis R.J., Hsia K., Spector S.A., et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Annals of Neurology 1997;42:679-88.
65. Ellis R.J., Moore D.J., Childers M.E., et al. Progression to neuropsychological impairment in Human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of Human Immunodeficiency virus RNA. Archives of Neurology 2002;59:923-8.
66. Zink M.C., Clements J.E. The two faces of HIV infection of cerebrospinal fluid: response. Trends in Microbiology 2000;8:390-1.
67. McArthur J.C., Hoover D.R., Bacellar M.A., et al. Dementia in AIDS patients: incidence and risk factors. Neurology 1993;43:2245-52.
68. Portegies P., de Gans J., Lange J.M., et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. British Medical Journal 1989:299;819-21.
69. Graham N.M., Hoover D.R., Park L.P., et al. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group. Annals of Internal Medicine 1996;124:1031-8.
70. Dore G.J., Cooper D.A., Pozniak A.L., et al. Eficacy of Tenofovir Disoproxil Fumarate in antiretroviral therapy naïve and experienced patients coinfected with HIV-1 and Hepatitis B Virus. Journal of Infectious Diseases 2004; 189:1185-92.
71. Sacktor N.C., Lyles R.H., Skolasky R.L., et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homossexual men. Multicenter AIDS Cohort Study (MACS). Neurology 1999;52:1640-7.
72. Maschke M., Kastrup O., Esser S., et al. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). Journal of Neurology, Neurosurgery and Psychiatry 2000;69:376-80.
73. Clifford D.B. AIDS dementia. Medical Clinics of North America 2002;86:537-50.
74. Gartner S. HIV infection and dementia. Science 2000;287:602-4.
75. Levy J.A., Hollander H., Shimabukuro J., Mills J. Isolation of DIDS associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet 1985;14:586-8.
76. Major E.O., Rausch D., Marra C., Clifford D. HIV- associated dementia. Science 2000;288:440-1.
77. Harrison M.J.G. Guidelines for management of HIV associated dementia, myelopathy, neuropathy and myopathy. Internal Journal of STD & AIDS 1998;9:390-3.
78. Polich J., Ilan A., Poceta J.S., et al. Neuroelectric assessment of HIV: EEG, ERP and viral load. Internal Journal of Psychophysiology 2000;38:97-108.
79. Power C., Selnes O.A., Grim J.A., McArthur J.C. HIV dementia scale: a rapid screening test. Journal of AIDS and Hum Retrovirology 1995;8:273-8.
80. 2 microglobulina and neopterin. Journal of Infectious Diseases 1996;174: 294-8.
81. McArthur J.C. NeuroAIDS: diagnosis and management. Hosp Pract 1997;15:73-97.
82. Schifitto G., Kieburtz K., McDermott M.P., et al. Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology 2001;56:415-8.
83. Butters N., Grant I., Haxby J., et al. Assessment of AIDS-related cognitive changes: recommendations of the NIMH Workshop on Neuropsychological Assessment Approaches. Journal of Clinical and Experimental Neuropsychology 1990;12:963-78.
84. Heaton R.K., Grant I., Butters N., et al. The HNRC 500 neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. Journal of the International Neuropsychological Society 1995;1:231-51.
85. McCutchan J.A., Letendre S. Pharmacology of antiretroviral drugs in the central nervous system: pharmacokinetics, antiretroviral resistance, and pharmacodynamics. In Neurology of AIDS, Second Edition. Gendelman H., Grant I., Everall I., Lipton S., and Swindells S. (eds.). Oxford University Press, 2005.
86. Lucette A.J., Cysique M.A., Maruff P., Brew J.B. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 2004;61:1699-704.
87. Letendre S.L., McCutchan J.A., Childers M.E., et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004;56:416-23.
88. Tan S.V, Guiloff R.J. Hypothesis on the pathogenesis of vacuolar myelopathy, dementia and peripheral neuropathy in AIDS. Journal of Neurology, Neurosurgery and Psychiatry 1998;65:23-8.